Cellectar Biosciences Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cellectar Biosciences stock.
View analyst ratings for Cellectar Biosciences or view top-rated stocks.

Wall Street analysts have given Cellectar Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cellectar Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cellectar Biosciences saw a increase in short interest in July. As of July 15th, there was short interest totaling 1,590,000 shares, an increase of 40.7% from the June 30th total of 1,130,000 shares. Based on an average trading volume of 772,300 shares, the days-to-cover ratio is currently 2.1 days. Currently, 3.4% of the company's shares are short sold.
View Cellectar Biosciences' Short Interest.

Cellectar Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Cellectar Biosciences.

Cellectar Biosciences, Inc. (NASDAQ:CLRB) released its quarterly earnings data on Sunday, May, 9th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.03.
View Cellectar Biosciences' earnings history.

Cellectar Biosciences' stock was trading at $1.80 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CLRB stock has decreased by 39.4% and is now trading at $1.09.
View which stocks have been most impacted by COVID-19.

Cellectar Biosciences shares reverse split on Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split.

3 brokerages have issued 1 year price targets for Cellectar Biosciences' stock. Their forecasts range from $3.00 to $5.50. On average, they expect Cellectar Biosciences' stock price to reach $4.25 in the next twelve months. This suggests a possible upside of 289.9% from the stock's current price.
View analysts' price targets for Cellectar Biosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Cellectar Biosciences include Adicet Bio (ACET), Alpine Immune Sciences (ALPN), Trevena (TRVN), Sensei Biotherapeutics (SNSE), Sol-Gel Technologies (SLGL), CorMedix (CRMD), Kala Pharmaceuticals (KALA), BELLUS Health (BLU), CTI BioPharma (CTIC), TFF Pharmaceuticals (TFFP), Sierra Oncology (SRRA), Spruce Biosciences (SPRB), Galera Therapeutics (GRTX), 180 Life Sciences (ATNF) and Pieris Pharmaceuticals (PIRS).
View all of CLRB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), (ECA), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM).

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

Cellectar Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Cozad Asset Management Inc. (0.06%). Company insiders that own Cellectar Biosciences stock include Dov Elefant, James V Caruso, Jarrod Longcor and Stephen A Hill.
View institutional ownership trends for Cellectar Biosciences.

CLRB stock was purchased by a variety of institutional investors in the last quarter, including Cozad Asset Management Inc.. Company insiders that have bought Cellectar Biosciences stock in the last two years include Dov Elefant, James V Caruso, Jarrod Longcor, and Stephen A Hill.
View insider buying and selling activity for Cellectar Biosciences or or view top insider-buying stocks.

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLRB stock can currently be purchased for approximately $1.09.

Cellectar Biosciences has a market capitalization of $57.48 million. The biopharmaceutical company earns $-15,090,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

Cellectar Biosciences employs 11 workers across the globe.

The official website for Cellectar Biosciences is www.cellectar.com.

Cellectar Biosciences is headquartered at 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932.

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]